Literature DB >> 8056454

Human neurological cancer cells express interleukin-4 (IL-4) receptors which are targets for the toxic effects of IL4-Pseudomonas exotoxin chimeric protein.

R K Puri1, P Leland, R J Kreitman, I Pastan.   

Abstract

Glioblastoma, glioma or neuroblastoma cells were examined for the expression of IL-4 receptors (IL-4R) by flow cytometric analysis and 125I-IL-4 binding. These cancer cell lines expressed IL-4R which were of high affinity (KD = 700 x 10(-12) M) on glioblastoma cells. To investigate the function of these receptors and to target potent cytotoxic antitumor agents to human neurological cancers, we utilized IL4-PE4E, which is composed of IL-4 and mutant Pseudomonas exotoxin (IL4-PE4E). This chimeric molecule was cytotoxic toward human glioblastoma, neuroblastoma and glioma tumor cells in a dose-dependent manner. The cytotoxicity of IL4-PE4E was specific, since it was neutralized by excess IL-4, and by an anti-IL-4 monoclonal antibody in all types of brain tumor tested. IL2-PE4E and IL6-PE4E were not cytotoxic, nor was an IL4-PE4E mutant lacking ADP-ribosylating activity, indicating the IL4-PE4E-mediated cytotoxicity of the brain tumor cells required both IL-4R binding and enzymatic toxin activity. These data indicate that human neurological cancer cells express IL-4R which are targets for the cytotoxic effects of IL4-toxin. In addition, our data also suggest that IL4-PE4E should be studied further as a potential treatment for human neurological cancers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8056454     DOI: 10.1002/ijc.2910580421

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  37 in total

1.  Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.

Authors:  S R Husain; P Gill; R J Kreitman; I Pastan; R K Puri
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

2.  Convection-enhanced drug delivery of interleukin-4 Pseudomonas exotoxin (PRX321): increased distribution and magnetic resonance monitoring.

Authors:  Y Mardor; D Last; D Daniels; R Shneor; S E Maier; D Nass; Z Ram
Journal:  J Pharmacol Exp Ther       Date:  2009-05-28       Impact factor: 4.030

3.  Neural stem cell-based gene therapy for brain tumors.

Authors:  Seung U Kim
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

4.  Interleukin-4 receptor-targeted liposomal doxorubicin as a model for enhancing cellular uptake and antitumor efficacy in murine colorectal cancer.

Authors:  Chih-Yung Yang; Hong-Wen Liu; Ya-Ching Tsai; Ju-Yu Tseng; Shu-Ching Liang; Chin-Yau Chen; Wei-Nan Lian; Ming-Cheng Wei; Maggie Lu; Ruey-Hwa Lu; Chi-Hung Lin; Jeng-Kai Jiang
Journal:  Cancer Biol Ther       Date:  2015-10-05       Impact factor: 4.742

Review 5.  Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementation.

Authors:  Marianela Candolfi; Kurt M Kroeger; Weidong Xiong; Chunyan Liu; Mariana Puntel; Kader Yagiz; Akm Ghulam Muhammad; Yohei Mineharu; David Foulad; Mia Wibowo; Hikmat Assi; Gregory J Baker; Pedro R Lowenstein; Maria G Castro
Journal:  Anticancer Agents Med Chem       Date:  2011-10       Impact factor: 2.505

Review 6.  Experimental approaches for the treatment of malignant gliomas.

Authors:  Leopold Arko; Igor Katsyv; Grace E Park; William Patrick Luan; John K Park
Journal:  Pharmacol Ther       Date:  2010-06-08       Impact factor: 12.310

Review 7.  Combining cytotoxic and immune-mediated gene therapy to treat brain tumors.

Authors:  James F Curtin; Gwendalyn D King; Marianela Candolfi; Remy B Greeno; Kurt M Kroeger; Pedro R Lowenstein; Maria G Castro
Journal:  Curr Top Med Chem       Date:  2005       Impact factor: 3.295

Review 8.  Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.

Authors:  Katherine Venmar Bankaitis; Barbara Fingleton
Journal:  Clin Exp Metastasis       Date:  2015-09-18       Impact factor: 5.150

Review 9.  Challenges in clinical design of immunotherapy trials for malignant glioma.

Authors:  Cleo E Rolle; Sadhak Sengupta; Maciej S Lesniak
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

Review 10.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.